Xenimmune
Cambridge, US · 1 known investors
XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses. Its lead therapy has shown proof of concept in common tumor types in in vitro and in vivo settings.
Investors · 1
Frequently asked questions
- What does Xenimmune do?
- XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses. Its lead therapy has shown proof of concept in common tumor types in in vitro and in vivo settings.
- Who are Xenimmune's investors?
- Xenimmune's investors include Cure Ventures.
- Where is Xenimmune headquartered?
- Xenimmune is headquartered in Cambridge, US.